Usage And Safety
Side Effects
Infections and infestations : Common: Vulvovaginitis, balanitis and related genital infections, Urinary tract infection (including pyelonephritis and urosepsis) Uncommon: Fungal infection Metabolism and nutrition disorders . Very common: Hypoglycaemia (when used with sulphonylurea or insulin) Uncommon: Volume depletion, Thirst Rare: Diabetic ketoacidosisNervous system disorders : Common: DizzinessGastrointestinal disorders : Uncommon: Constipation, Dry mouth Skin and subcutaneous tissue disorders Common: Rash Musculoskeletal and connective tissue disorders : Common: Back pain Not Known: Fracture of BoneRenal and urinary disorders Common: Dysuria, Polyuria Uncommon: Nocturia, Renal impairmentReproductive system and breast disorders Uncommon: Vulvovaginal pruritus, Pruritus genital
Drug Interactions
ACE inhibitors , Flouroquinolones , Somatostatin Analogues , SGLT2 inhibitors
Indication
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
When not to Use
Contraindications : History of a serious hypersensitivity reaction to dapagliflozin.Severe renal impairment, end-stage renal disease (ESRD), or patients on dialysis.
Warnings
Warning 1
Insulin and insulin secretagogues are known to cause hypoglycemia. It can increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with Dapagliflozin.
Warning 2
It should not be used in patients with active bladder cancer. In patients with prior history of bladder cancer, the benefits of glycemic control versus unknown risks for cancer recurrence with dapagliflozin should be considered.
Warning 3
It increases the risk of genital mycotic infections. Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections.
